FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080954673> ?p ?o ?g. }

• W3080954673 endingPage "2651" @default.
• W3080954673 startingPage "2651" @default.
• W3080954673 abstract "Abstract Introduction: The transcriptional kinase CDK7 has been implicated in the pathogenesis of multiple malignancies, including hematologic malignancies, and may play important roles in regulation of oncogenic transcriptional dependencies and in regulation of the mitochondrial apoptosis machinery in tumors. SY-1365, a selective inhibitor of CDK7, was developed to exploit tumor dependencies driven by CDK7 and is in clinical development in patients with advanced solid tumors. We have previously reported that SY-1365 selectively induces apoptosis in leukemic cells relative to non-malignant cells in vitro, and demonstrates anti-tumor activity in AML xenografts. Here we report that SY-1365 has potent inhibitory activity against a broad panel of hematologic malignancies in vitro and ex vivo, induces regressions in AML xenografts using a clinically relevant dosing regimen, and demonstrates synergy with the BCL2 inhibitor venetoclax in AML cells in vitro. Methods: SY-1365 dose-response curves were measured using the ATP-lite assay in a panel of 85 leukemia and lymphoma cell lines in vitro, and in a panel of 226 patient-derived tumor samples from 5 leukemic indications cultured ex vivo. In vivo tumor inhibitory activity was evaluated using once weekly (QW) and twice weekly (BIW) dosing regimens in ML-2 and Kasumi-1 AML xenografts. Growth-rate (GR) adjusted dose response curves were used to classify cell lines into low and high sensitivity groups, and were evaluated relative to RNA expression data to identify markers predictive of sensitivity to SY-1365. Synergy between SY-1365 and venetoclax was evaluated in vitro using KG-1 AML cells. Results: In 42 leukemia lines, SY-1365 had a median IC50 of 11nM (range 1-79nM), with 48% (20/42) demonstrating particularly low IC50s ( Conclusions: SY-1365 shows potent in vitro inhibitory activity in multiple hematological indications and can induce AML xenograft tumor regression in mice. In vitro exploratory biomarker and tumor cell inhibitory combination studies in AML suggest a role for mitochondrial apoptosis signaling in mediating sensitivity to SY-1365 and support the evaluation of a combination with venetoclax. SY-1365 is currently being assessed in a phase 1 trial in adult patients with advanced solid tumors (NCT03134638). The results described here support the potential for additional exploration in patients with hematological malignancies. Disclosures Hodgson: Syros Pharmaceuticals: Employment, Equity Ownership. Johannessen: Syros Pharmaceuticals: Employment, Equity Ownership. Rajagopal: Syros Pharmaceuticals: Employment, Equity Ownership. Hu: Syros Pharmaceuticals: Employment, Equity Ownership. Orlando: Syros Pharmaceuticals: Employment, Equity Ownership. Eaton: Syros Pharmaceuticals: Employment, Equity Ownership. McKeown: Syros Pharmaceuticals: Employment. Tyner: Takeda Pharmaceutical Company: Research Funding; Agios Pharmaceuticals: Research Funding; Incyte Corporation: Research Funding; Gilead: Research Funding; Janssen Pharmaceutica: Research Funding; Syros: Research Funding; Aptose Biosciences: Research Funding; Seattle Genetics: Research Funding; Constellation Pharmaceuticals: Research Funding; Genentech: Research Funding; Array Biopharma: Research Funding; AstraZeneca: Research Funding; Leap Oncology: Consultancy. Sprott: Syros Pharmaceuticals: Employment, Equity Ownership. Fritz: Syros Pharmaceuticals: Employment, Equity Ownership. Di Tomaso: Syros Pharmaceuticals: Employment." @default.
• W3080954673 created "2020-09-01" @default.
• W3080954673 creator A5018710860 @default.
• W3080954673 creator A5019864381 @default.
• W3080954673 creator A5023553117 @default.
• W3080954673 creator A5030772451 @default.
• W3080954673 creator A5032144639 @default.
• W3080954673 creator A5032421989 @default.
• W3080954673 creator A5047133226 @default.
• W3080954673 creator A5058340446 @default.
• W3080954673 creator A5058432610 @default.
• W3080954673 creator A5075070858 @default.
• W3080954673 creator A5075185822 @default.
• W3080954673 creator A5089343289 @default.
• W3080954673 date "2017-12-07" @default.
• W3080954673 modified "2023-09-28" @default.
• W3080954673 title "Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia" @default.
• W3080954673 doi "https://doi.org/10.1182/blood.v130.suppl_1.2651.2651" @default.
• W3080954673 hasPublicationYear "2017" @default.
• W3080954673 type Work @default.
• W3080954673 sameAs 3080954673 @default.
• W3080954673 citedByCount "1" @default.
• W3080954673 countsByYear W30809546732022 @default.
• W3080954673 crossrefType "journal-article" @default.
• W3080954673 hasAuthorship W3080954673A5018710860 @default.
• W3080954673 hasAuthorship W3080954673A5019864381 @default.
• W3080954673 hasAuthorship W3080954673A5023553117 @default.
• W3080954673 hasAuthorship W3080954673A5030772451 @default.
• W3080954673 hasAuthorship W3080954673A5032144639 @default.
• W3080954673 hasAuthorship W3080954673A5032421989 @default.
• W3080954673 hasAuthorship W3080954673A5047133226 @default.
• W3080954673 hasAuthorship W3080954673A5058340446 @default.
• W3080954673 hasAuthorship W3080954673A5058432610 @default.
• W3080954673 hasAuthorship W3080954673A5075070858 @default.
• W3080954673 hasAuthorship W3080954673A5075185822 @default.
• W3080954673 hasAuthorship W3080954673A5089343289 @default.
• W3080954673 hasConcept C190283241 @default.
• W3080954673 hasConcept C203014093 @default.
• W3080954673 hasConcept C207001950 @default.
• W3080954673 hasConcept C26291073 @default.
• W3080954673 hasConcept C2777938653 @default.
• W3080954673 hasConcept C2778461978 @default.
• W3080954673 hasConcept C2779675984 @default.
• W3080954673 hasConcept C502942594 @default.
• W3080954673 hasConcept C54355233 @default.
• W3080954673 hasConcept C55493867 @default.
• W3080954673 hasConcept C86803240 @default.
• W3080954673 hasConcept C98274493 @default.
• W3080954673 hasConceptScore W3080954673C190283241 @default.
• W3080954673 hasConceptScore W3080954673C203014093 @default.
• W3080954673 hasConceptScore W3080954673C207001950 @default.
• W3080954673 hasConceptScore W3080954673C26291073 @default.
• W3080954673 hasConceptScore W3080954673C2777938653 @default.
• W3080954673 hasConceptScore W3080954673C2778461978 @default.
• W3080954673 hasConceptScore W3080954673C2779675984 @default.
• W3080954673 hasConceptScore W3080954673C502942594 @default.
• W3080954673 hasConceptScore W3080954673C54355233 @default.
• W3080954673 hasConceptScore W3080954673C55493867 @default.
• W3080954673 hasConceptScore W3080954673C86803240 @default.
• W3080954673 hasConceptScore W3080954673C98274493 @default.
• W3080954673 hasLocation W30809546731 @default.
• W3080954673 hasOpenAccess W3080954673 @default.
• W3080954673 hasPrimaryLocation W30809546731 @default.
• W3080954673 hasRelatedWork W1978573162 @default.
• W3080954673 hasRelatedWork W2035070890 @default.
• W3080954673 hasRelatedWork W2885696827 @default.
• W3080954673 hasRelatedWork W2909212413 @default.
• W3080954673 hasRelatedWork W2911058200 @default.
• W3080954673 hasRelatedWork W2944568957 @default.
• W3080954673 hasRelatedWork W2954243543 @default.
• W3080954673 hasRelatedWork W2956080317 @default.
• W3080954673 hasRelatedWork W2965231077 @default.
• W3080954673 hasRelatedWork W2979549156 @default.
• W3080954673 hasRelatedWork W2979693957 @default.
• W3080954673 hasRelatedWork W2983461072 @default.
• W3080954673 hasRelatedWork W2983490414 @default.
• W3080954673 hasRelatedWork W2983972007 @default.
• W3080954673 hasRelatedWork W2984508326 @default.
• W3080954673 hasRelatedWork W2984733040 @default.
• W3080954673 hasRelatedWork W2987729487 @default.
• W3080954673 hasRelatedWork W2993812536 @default.
• W3080954673 hasRelatedWork W3095089007 @default.
• W3080954673 hasRelatedWork W3096629671 @default.
• W3080954673 hasVolume "130" @default.
• W3080954673 isParatext "false" @default.
• W3080954673 isRetracted "false" @default.
• W3080954673 magId "3080954673" @default.
• W3080954673 workType "article" @default.